Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CONFIRM
  • Sponsors Biogen; Biogen Idec

    • Most Recent Events

    • 15 Apr 2023 Results post hoc pooled analysis from DEFINE, CONFIRM, and ENDORSE evaluating safety and efficacy of DMF in a subgroup of young adults aged 18-29 years, published in the Neurology and Therapy
    • 26 Apr 2022 Data from 3studies (ASCEND, DEFINE & CONFIRM) were used to predict treatment response with MRI-based sub-typing SuStaIn in relapsing and secondary progressive MS, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
    • 15 Apr 2021 According to a Biogen media release, based on the data from DEFINE and CONFIRM studies, National Medical Products Administration (NMPA) has approved TECFIDERA (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top